Table 1.
Characteristics of study participants
| Characteristic | Overall (n = 1119) | Active treatment (n=656) | Placebo (n=463) |
|---|---|---|---|
| Age, years | 48 (37–59) | 47 (36–58) | 49 (37–59) |
| Male, n (%) | 255 (23) | 145 (22) | 110 (24) |
| Race, n (%) | |||
| White | 943 (85) | 553 (86) | 390 (85) |
| Black | 42 (4) | 27 (4) | 15 (3) |
| Other | 134 (12) | 76 (12) | 58 (13) |
| Height, cm | 163 (157–170) | 163 (157–170) | 163 (157–170) |
| Weight, kg | 70.0 (59.1–81.5) | 69.1 (58.0–81.4) | 70.0 (60.3–81.6) |
| BMI, kg/m2 | 25.9 (22.5–30.0) | 25.7 (22.2–29.8) | 26.0 (22.8–30.3) |
| PAH diagnosis, n (%) | |||
| Idiopathic | 637 (60) | 374 (60) | 263 (60) |
| Connective tissue disease | 247 (23) | 147 (24) | 100 (23) |
| HIV/anorexigen use | 10 (1) | 5 (1) | 5 (1) |
| Congenital heart disease | 169 (16) | 98 (16) | 71 (16) |
| NYHA functional classification, n (%) | |||
| I/II | 599 (55) | 326 (51) | 273 (62) |
| III/IV | 482 (45) | 312 (49) | 170 (38) |
| Baseline hemodynamics | |||
| RAP, mm Hg | 8.0 (5.0–12.0) | 8.0 (5.0–12.0) | 8.0 (5.0–12.0) |
| mPAP, mm Hg | 55.0 (46.0–65.0) | 55.0 (46.0–64.0) | 56.0 (47.0–67.0) |
| Cardiac output, L/min | 3.8 (3.1–4.8) | 3.8 (3.2–4.9) | 3.8 (3.1–4.6) |
| Cardiac index, L/min/m2 | 2.1 (1.8–2.6) | 2.2 (1.8–2.8) | 2.1 (1.8–2.5) |
| PCWP, mm Hg | 9.0 (6.0–11.0) | 9.0 (6.0–11.0) | 9.0 (6.0–12.0) |
| PVR, Wood units | 11.9 (8.4–16.8) | 11.6 (7.9–16.5) | 12.4 (8.9–17.0) |
| PA compliance, mL/mmHg | 0.93 (0.68–1.33) | 0.95 (0.71–1.40) | 0.88 (0.65–1.23) |
| Sodium, mEq/L | 140 (138–142) | 140 (138–142) | 140 (138–142) |
| Warfarin use, n (%) | 582 (63) | 338 (61) | 244 (67) |
| Baseline 6MWD, m | 352 (281–409) | 355 (288–408) | 348 (273–410) |
| Study, n (%) | |||
| AIR | 202 (18) | 101 (15) | 101 (22) |
| SUPER | 269 (24) | 204 (31) | 65 (14) |
| STRIDE-1 | 178 (16) | 118 (18) | 60 (13) |
| Treprostinil | 470 (42) | 233 (36) | 237 (51) |
Summaries provided as median (Q1–Q3) unless otherwise indicated by n (%). BMI=body mass index; HIV=human immunodeficiency virus; NYHA=New York Heart Association; RAP=right atrial pressure; PAP=pulmonary artery pressure; PCWP=pulmonary capillary wedge pressure; PVR=pulmonary vascular resistance; PA=pulmonary artery; AIR=Aerosolized Iloprost Randomized; STRIDE=Sitaxsentan To Relieve Impaired Exercise; SUPER=Sildenafil Use in Pulmonary Hypertension.